^
    Back
    Association details:
    Biomarker:BRAF D594G
    Cancer:Non Small Cell Lung Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Thorac Oncol
    Title:

    Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations

    Published date:
    06/12/2020
    Excerpt:
    Three patients were treated with MEK +/- BRAF inhibitors. Patients harboring G469V and D594G mutations did not respond, while a patient with L597R mutation had durable response.
    DOI:
    10.1016/j.jtho.2020.05.021